NCT00179582终止不适用
A Randomized, Multi-center, Double-blind, Placebo Controlled, Dose Ranging Study With VSL#3 in Diarrhea Predominant IBS Patients
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 180
- 试验地点
- 2
- 主要终点
- Global improvement in IBS symptoms
研究概览
简要总结
To evaluate the effects of VSL#3 on symptoms associated with diarrhea predominant IBS
详细描述
The study will evaluate 2 doses of VSL#3 and placebo over a 4 week period in patients presenting with diarrhea predominant IBS symptoms.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •IBS diarrhea
排除标准
- •< 18 years of age
- •Pregnancy/breast feeding
- •concomitant medications to reduce bowel function
结局指标
主要结局
Global improvement in IBS symptoms
次要结局
- Changes in abdominal pain
- Frequency of bowel movements
- Changes in bloating
研究者
Anthony Lembo
Associate Professor of Medicine
Beth Israel Deaconess Medical Center
研究点 (2)
Loading locations...
相似试验
终止
1 期
The Use of VSL#3 in Irritable Bowel Syndrome in ChildrenIrritable Bowel SyndromeNCT00932841Dayton Children's Hospital15
已完成
2 期
Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)Diarrhea-predominant Irritable Bowel SyndromeNCT03977155Boston Pharmaceuticals133
Unknown
2 期
The Effect of Coltect (Selenium, Curcumin and Green Tea) on Irritable Bowel SyndromeIrritable Bowel SyndromeNCT01167673NAFTALI TIMNA40
已完成
不适用
The Effect of Neu-P11 on Symptoms in Patients With D-IBSDiarrhea- Irritable Bowel SyndromeNCT01558284Ludwig-Maximilians - University of Munich40
已完成
2 期
Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)Irritable Bowel SyndromeNCT01327300University of Florida7